Figure 2.
Figure 2. Inhibition of angiogenesis in mice immunized against angiogenesis-associated products. Mice were immunized 3 times with DCs transfected with VEGF (A) or VEGFR-2 (B) mRNA or injected with PBS (C). The angiogenic potential was determined using the dorsal skin-fold window-chamber assay. At 4 weeks following immunization, mice were implanted with window chambers and 5 days later inoculated with GFP-expressing B16 melanoma cells. Tumor growth and neovascularization were followed by light and fluorescent microscopy starting 4 days after tumor implantation. Representative pictures taken by light microscopy (left) and fluorescent microscopy to localize the implanted GFP-expressing tumor (right) from 2 mice per group are shown 14 days after tumor implantation.

Inhibition of angiogenesis in mice immunized against angiogenesis-associated products. Mice were immunized 3 times with DCs transfected with VEGF (A) or VEGFR-2 (B) mRNA or injected with PBS (C). The angiogenic potential was determined using the dorsal skin-fold window-chamber assay. At 4 weeks following immunization, mice were implanted with window chambers and 5 days later inoculated with GFP-expressing B16 melanoma cells. Tumor growth and neovascularization were followed by light and fluorescent microscopy starting 4 days after tumor implantation. Representative pictures taken by light microscopy (left) and fluorescent microscopy to localize the implanted GFP-expressing tumor (right) from 2 mice per group are shown 14 days after tumor implantation.

Close Modal

or Create an Account

Close Modal
Close Modal